New Delhi: Biotechnology Firm Novavax Inc.
said he had completed the filing of rolling for an emergency use list (EUL) from the Covid-19 vaccine candidate to the World Health Organization (WHO).
Previously on Monday, Novavax and the Serum Institute of India (SII) said that they had received authorization of the first emergency use (EUA) for the Covid-19 vaccine in Indonesia.
“The company has now completed submissions to the World Health Organization (WHO) of all modules needed for the evaluation of NVX-COV2373 regulations, Covid-19 vaccines based on company recomborate nanoparticles with the Matrix-M Ajuvant,” said Novavax Inc.
statement on Thursday.
Chemical modules, manufacturing and control are submitted to WHO, as well as other supervisory agencies around the world, utilizing the Novavax manufacturing partnership with SII, the largest vaccine producer in the world with volume, he added.
Novavax will make further shipment to enable vaccine supplies from additional manufacturing sites in the Novavax global supply chain.
Submission by Novavax is an addition to the previous submission to whom with Novavax and SII, said the company.
“Today’s shipments reflect our sustainable focus on the acceleration of access and distribution that is fair when we work to bring our vaccines to people in need throughout the world,” said President Novavax and Chief Executive Stanley C Erck.
WHO EUL grant is a prerequisite for exporting to many countries participating in the Covax facility, which was established to allocate and distribute the vaccine equivalent to participating countries and economics, Novavax Inc.
said.
The company continues to work with the government, the supervisory and non-governmental organizational authorities in its commitment to ensure fair global access to the Covid-19 vaccine, he added.